Evidence map›Paper›PMID 39612130›Full record

ReviewClinical reviews in allergy & immunology2024

Advancements in the Study of the Immune Molecule NKp46 in Immune System-related Diseases.

Siyi Qian, Yanhong Zhou, Zhongyuan Jin, Xiang Li, Yuxuan Tian, Fuxin Chen, Bin Zhang, Zhipeng Yan

Abstract readReview
In one paragraph

Review in Clinical reviews in allergy & immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siyi QianThe 2nd Department of Gynecology Oncology of Hunan Cancer Hospital the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, People's Republic of China.
Yanhong ZhouCancer Research Institute, Basic School of Medicine Sciences, Central South University, Changsha, Hunan, 410078, People's Republic of China.
Zhongyuan JinDepartment of Pathology, Xiangya Medical School, Central South University, Changsha, People's Republic of China.
Xiang LiDepartment of Pathology, Xiangya Medical School, Central South University, Changsha, People's Republic of China.
Yuxuan TianDepartment of Histology and Embryology, Basic School of Medicine Sciences, Central South University, Changsha, Hunan, 410013, People's Republic of China.
Fuxin ChenDepartment of Histology and Embryology, Basic School of Medicine Sciences, Central South University, Changsha, Hunan, 410013, People's Republic of China.
Bin ZhangThe 2nd Department of Gynecology Oncology of Hunan Cancer Hospital the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, People's Republic of China. zhangbin@csu.edu.cn.
Zhipeng YanThe 2nd Department of Gynecology Oncology of Hunan Cancer Hospital the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, People's Republic of China. 15211075251@163.com.

Funding

National Natural Science Foundation of China 82073099Natural Science Foundation of Hunan Province 2024JJ5462
6 · The paper itself

Abstract

NKp46 is a natural killer cell activating receptor primarily expressed on NK cells and non-NK innate lymphoid cells. In the context of anti-infection, NKp46 activates NK cells by binding to ligands on pathogens or infected cells, enabling NK cells to kill the infected cells. In antitumor activities, NKp46 plays a pivotal role in combating tumor growth through mechanisms such as directly killing tumor cells, inhibiting tumor immune escape, and reducing tumor growth rate through immune editing. The expression levels of NKp46 are closely associated with the progression of immune-related diseases, viral infections, leukemia, tumors, and reproductive failure, affecting diagnosis and prognosis. However, the functionality and mechanistic actions of NKp46, as well as the identification of additional NKp46 ligands, require further investigation. This review provides a comprehensive understanding of NKp46, offering a theoretical foundation for the research and development of diagnostic and therapeutic approaches for related diseases.

Indexed as

Killer Cells, NaturalNatural Cytotoxicity Triggering Receptor 1NeoplasmsAnimalsDisease SusceptibilityHumansImmune System DiseasesNatural Cytotoxicity Triggering Receptor 1NCR1 protein, humanAutoimmunityInnate Lymphoid Cells (ILC)Natural Cytotoxicity Receptors (NCR)Natural killer cellsNKp46Tumor immunology

Identifiers

PMID39612130
PMCPMC11638288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.